Acalabrutinib

Acalabrutinib

Systematic (IUPAC) name
4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide
Identifiers
CAS Number	1420477-60-6
ChemSpider	36764951
Chemical data
Formula	C26H23N7O2
Molar mass	465.507 g/mol
SMILES CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5
InChI InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1 Key:WDENQIQQYWYTPO-IBGZPJMESA-N

Acalabrutinib (rINN,^[1] ACP-196) is an experimental anti-cancer drug and a 2nd generation BTK inhibitor^[2] developed by Acerta Pharma.^[3]

It is designed to be more selective (fewer side-effects) than ibrutinib.^[2]

As of 2015 it is in late stage clinical trials for relapsed chronic lymphocytic leukemia. Interim results are encouraging : 95% overall response rate.^[2][4]

It is also in another 20 clinical trials (alone and in combination) for various cancers.^[4][5]

References

1. "WHO Drug Information - recommended INN" (PDF). WHO Drug Information. World Health Oorganisation. Retrieved 24 December 2015.
2. Byrd; et al. (2015). "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.". doi:10.1056/NEJMoa1509981.
3. "AstraZeneca to buy Acerta for blood cancer drug". www.rsc.org. Chemistry World - Royal Society of Chemistry. Retrieved 24 December 2015.
4. Acerta Pharma Announces Study Published in New England Journal of Medicine Demonstrates Acalabrutinib (ACP-196) Shows Marked Activity in Relapsed Chronic Lymphocytic Leukemia
5. 21 studies found for: ACP-196